PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jan 20, 2023

byprotokinetixp

Change a Life. Invest in Retinal Replacement

Patients with progressive degenerative eyesight, have been waiting for a cure. For years retinal replacement has been nothing but a wish. But with protoKinetix (PKTX) lives can be changed. PKTX...Read more

Jul 20, 2022

bybhenderson

ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants

Marietta, Ohio, July 20, 2022 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase...Read more

Jul 15, 2022

byprotokinetixp

AAGP® | Benefits of AAGP®

Why AAGP is a new method for skin protection

We risk skin damage every time we step into the sun, whether for work, play, or travel. The sun’s UV rays cause inflammation and sunburns, and sustained damage can lead...Read more

Jun 27, 2022

byprotokinetixp

Evolving Cell Therapies with AAGP

Advancements in medical science are making effective treatments more accessible than ever before. In its development of AAGP®, ProtoKinetix is opening the door to new cell therapies, as well as...Read more

Apr 19, 2022

byprotokinetixp

Own the future of anti-aging technology with ProtoKinetix (PKTX)

The world over, there is increased interest in the possibility of extending human longevity. What could our lives look like if we had more control over our cells? If we...Read more

Jan 14, 2022

bybhenderson

ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only

Marietta, Ohio, January 14, 2022- ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it will hold its Annual General Meeting of the...Read more

Jan 14, 2022

byprotokinetixp

ProtoKinetix Announces Annual General Stockholder Meeting - Virtual

Investors in ProtoKinetix, Inc., are invited to attend the annual shareholder meeting at 4 p.m. EST on Feb. 11, 2022. Join the meeting online at http://www.virtualshareholdermeeting.com/PKTX2022.

Nov 23, 2021

bybhenderson

ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease

Marietta, Ohio, November 23, 2021 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging...Read more

Nov 16, 2021

byprotokinetixp

Biotech Investing

Many biotech companies have seen soaring valuations as rapid advances in biotechnology have resulted in innovative new therapies. But how can wary investors find the right companies to back —...Read more

May 12, 2021

bybhenderson

ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions

Marietta, Ohio, May 12, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.